What is the Suraksha Diagnostic PE ratio today?
Suraksha Diagnostic's PE ratio is 46.5 at the 29 October 2026 close (₹319.55 a share): a market capitalisation of ₹1,664 crore divided by consolidated net profit of ₹35.8 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹32.2 crore) it is 51.7.
What is the Suraksha Diagnostic ROE and ROCE?
In FY26, Suraksha Diagnostic's return on equity (ROE) was 14.1% and its return on capital employed (ROCE) was 15.9%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities).
What is the Suraksha Diagnostic book value per share?
Suraksha Diagnostic's book value per share was ₹47.01 on 31 March 2026: shareholders' equity of ₹245 crore divided by the 5.21 crore shares in issue, up 15.9% from ₹40.56 a year earlier. The share price at the 29 October 2026 close was ₹319.55.
What is the Suraksha Diagnostic PB ratio (price to book value)?
Suraksha Diagnostic's price-to-book (PB) ratio is 6.80 at the 29 October 2026 close: a market capitalisation of ₹1,664 crore divided by shareholders' equity (book value) of ₹245 crore on 31 March 2026. That is a book value of ₹47.01 per share against a share price of ₹319.55.
What is the Suraksha Diagnostic debt to equity ratio?
Suraksha Diagnostic's debt-to-equity ratio was 0.01 on 31 March 2026: borrowings of ₹1.7 crore against total equity of ₹243 crore. A year earlier, on 31 March 2025, it was 0.03.
What is the Suraksha Diagnostic dividend yield?
Suraksha Diagnostic's dividend yield is 0.16% at the 29 October 2026 close: dividends of ₹0.50 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹319.55. They were ₹0.50 on 15 September 2026.
What is the Suraksha Diagnostic market cap?
Suraksha Diagnostic's market capitalisation was ₹1,664 crore at the 29 October 2026 close: 5.21 crore shares at ₹319.55 each.
Is Suraksha Diagnostic debt free?
No. Suraksha Diagnostic had borrowings of ₹1.7 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.01. Its cash and current investments were ₹26.3 crore, so it held net cash of ₹24.6 crore.
What is the Suraksha Diagnostic dividend in 2026 and its record date?
In 2026, Suraksha Diagnostic has declared one dividend: ₹0.50 with record date 15 September 2026.
What is the Suraksha Diagnostic net worth?
Suraksha Diagnostic's net worth — shareholders' equity in its consolidated balance sheet — was ₹245 crore on 31 March 2026, up 15.9% from ₹211 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹1,664 crore at the 29 October 2026 close.
What is the Suraksha Diagnostic promoter holding?
Promoters held 49.10% of Suraksha Diagnostic on 30 September 2026, unchanged from the previous quarter and up 0.12 percentage points from 48.98% a year earlier, according to the shareholding pattern filed with NSE.
What is the Suraksha Diagnostic revenue and profit in FY26?
In FY26 (April 2025–March 2026), Suraksha Diagnostic's consolidated net profit was ₹32.2 crore, up 1.2% from ₹31.8 crore in FY25, on revenue from operations of ₹310 crore (up 23.1%).
What is the Suraksha Diagnostic EPS?
Suraksha Diagnostic's basic earnings per share (EPS) were ₹6.18 in FY26, against ₹5.97 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹6.88.
What is the Suraksha Diagnostic free cash flow?
In FY26, Suraksha Diagnostic generated ₹81.8 crore of cash from operations and spent ₹67.3 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹14.5 crore. In FY25 it was ₹21.3 crore.
When are the Suraksha Diagnostic next results?
Suraksha Diagnostic has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.
What is the Suraksha Diagnostic shareholding pattern?
On 30 September 2026, Suraksha Diagnostic's shares were held by promoters 49.10%, foreign portfolio investors (FII/FPI) 13.97%, domestic institutions (DII) 21.56% (including mutual funds at 20.16%) and retail and other non-institutional investors 15.37%. Over the year, FII holding was up 0.25 percentage points from 13.72% and DII holding was down 0.42 percentage points from 21.98%.
What are the Suraksha Diagnostic latest quarterly results?
Suraksha Diagnostic's latest results are for Q1 FY27 (April–June 2026), filed on 12 August 2026: consolidated net profit ₹13 crore, up 38.4% from ₹9.4 crore in Q1 FY26; revenue from operations ₹87.6 crore, up 20.7% year on year.
How does the Suraksha Diagnostic PE ratio compare with its peers?
At the 29 October 2026 closing prices, on FY26 net profit, Suraksha Diagnostic's PE ratio is 51.7, the third highest of the four: Krsnaa Diagnostics 15.9, Health X Platform 755.3 and Nephrocare Health Services 82.1, a peer average of 284.4. Each is the company's market capitalisation at that price divided by its FY26 net profit.
How does Suraksha Diagnostic compare with its peers?
On FY26 consolidated figures, against Krsnaa Diagnostics, Health X Platform and Nephrocare Health Services: Suraksha Diagnostic's operating margin of 17.4% is the highest of the four (Krsnaa Diagnostics 15.7%, Health X Platform −4.5%, Nephrocare Health Services 13.7%; peer average 8.3%); its return on equity of 14.1% is the highest of the four (Krsnaa Diagnostics 10.9%, Health X Platform 0.2%, Nephrocare Health Services 6.9%; peer average 6.0%).
Suraksha Diagnostic vs Krsnaa Diagnostics: how do they compare?
In FY26, Suraksha Diagnostic earned net profit of ₹32.2 crore on revenue of ₹310 crore, against ₹101 crore on ₹773 crore for Krsnaa Diagnostics. Suraksha Diagnostic's operating margin was 17.4% (Krsnaa Diagnostics 15.7%) and its return on equity 14.1% (Krsnaa Diagnostics 10.9%). At the 29 October 2026 close, Suraksha Diagnostic's market capitalisation was ₹1,664 crore against ₹1,615 crore for Krsnaa Diagnostics, and its PE ratio on FY26 profit 51.7 against 15.9.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
